focus -WSS

focus

author：comprehensive 2025-09-06 08:39:37 - browse：3

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Cholera vaccine supplies dangerously low, outbreaks surging

explore

hotspot

WSS

Redefining sustainability for the pharmaceutical industry

Readout Newsletter: Beam, Prozac, "TechBio" and more

Children’s Hospital revives plan for pedestrian bridge

Pfizer is about to make a big push in cancer. Will investors listen?

Children’s Hospital revives plan for pedestrian bridge

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

focus

focus

explore

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Tori Bowie and the unacceptable rates of Black maternal death

'Vaccine

Affirmative action in medical school literally saved lives

Measles policy set amid Florida outbreak alarms vaccine proponents

New air purifier tech could be key to improving indoor air quality

As AI regulations shape up, health tech startups beg for clarity

The cancer drug shortage isn’t new — and neither are the solutions

Cholera vaccine supplies dangerously low, outbreaks surging

focus

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Color Health wants to make cancer screenings convenient

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

As AI regulations shape up, health tech startups beg for clarity

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Opioid cravings were reduced by anti

explore

hotspot

hotspot

Wikipedia